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SUPPORTING ONLINE MATERIAL 
 
Materials and Methods 
Plant growth. Plants were grown on a soil:vermiculite:perlite (2:1:1) mixture at 20ºC under 
constant illumination with cool white fluorescent light, unless indicated otherwise. 
Tissue collection for gene expression profiling experiments. For all experiments, we used 
approximately 4 week-old 35S:AP1-GR ap1-1 cal-1 plants (S1). For each sample, 
inflorescence tissue from ~25 plants was collected using jeweler’s forceps as previously 
described (S1). At least four biologically independent sets of samples were generated for 
each experiment. For the time-course experiments, we treated inflorescences with a solution 
containing 10 µM dexamethasone (Sigma-Aldrich), 0.01% (v/v) ethanol, and 0.015% (v/v) 
Silwett L-77 (De Sangosse), or with an identical mock solution that lacked dexamethasone. 
Using plastic pipettes, the solutions were directly applied onto the inflorescences so that the 
cauliflower-like structures were completely drenched. We then collected inflorescence tissue 
after 2, 4, 8, and 12 hours, as well as from untreated plants (0 hour time point). For 
cycloheximide experiments, we treated inflorescences of 35S:AP1-GR ap1-1 cal-1 plants 
with a dexamethasone-containing or a mock solution (as described above), or with identical 
solutions that contained in addition 10 µM cycloheximide (Sigma-Aldrich). Tissue was 
collected 3 hours after the treatment. For qRT-PCR experiments, tissue was collected from 
untreated control plants, and from plants 12 hours after treatment with either a 
dexamethasone-containing or a mock solution (as described above).  
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RNA preparation. Total RNA was isolated from tissue samples using the Plant Total RNA 
kit (Sigma-Aldrich) according to the manufacturer’s instructions. Quality of RNA samples 
was evaluated using a Bioanalyzer and a RNA Nano 6000 kit (Agilent). RNA concentrations 
were determined using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific). 
Total RNA preparations used for qRT-PCR analysis were treated with DNase I (Ambion) to 
reduce contaminations with genomic DNA. 
Microarray setup and experiments. Two different microarray platforms were used in the 
study:  microarrays that were based on the Arabidopsis Genome Oligo Set Version 1.0 and 
on the Arabidopsis Genome Oligo Set Version 1.0 Upgrade (Operon, Huntsville, AL), and 
hereafter referred to as "Operon microarrays"; and custom microarrays manufactured by 
Agilent (Agilent Technologies, Santa Clara, CA), and hereafter referred to as "Agilent 
microarrays". The Operon microarrays were prepared as previously described (S2), and 
consist of a total of 30,194 70-mer oligonucleotide probes that correspond to 26,215 
annotated genes according to The Arabidopsis Information Resource (TAIR) genome 
annotation version 8. Agilent microarrays (version 1) were designed using the eArray 
software pipeline (https://earray.chem.agilent.com/earray/) and TAIR genome annotation v7, 
and contain 26,566 60-mer probes corresponding to the same number of annotated genes 
(pseudogenes, transposons, retrotransposons, and pre-tRNAs were excluded from the 
design).  A second-generation Arabidopsis custom eArray was designed using TAIR 
genome annotation v8, and contains probes corresponding to 28,327 annotated genes. The 
same sets of RNA samples were analyzed using both the Operon and Agilent microarrays.   
Operon microarrays were used as previously described (S1), except that the Amino 
Allyl MessageAmpII aRNA Amplification Kit (Applied Biosystems/Ambion, Austin, TX) 
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was used for labeling of RNA samples with Cy3 and Cy5 fluorescent dyes, following 
manufacturer's instructions. Microarrays were scanned with both Axon GenePix 4200A and 
Axon 4000B scanners, using the Gene Pix 5.0 analysis software (Molecular Devices, 
Sunnyvale, CA). 
Agilent microarrays were used following manufacturer's instructions.  RNA samples 
were labeled with fluorescent dyes using the Quick Amp Labeling Kit (Agilent).  Microarray 
hybridizations (65ºC, 16h) and washes were performed with Agilent reagents and following 
standard protocols. Microarrays were scanned using an Agilent DNA Microarray Scanner 
G2565CA, and data were acquired using Agilent's Feature Extraction Software version 
9.5.3.1. Agilent version 1 custom microarrays were used for the time series experiments, 
whereas version 2 microarrays were used for the cycloheximide experiment (see below). 
Four independent sets of biological samples were used for the experiments, and 
sample setup and pairing for hybridizations was the same for Operon and Agilent 
microarrays. In each of the biological replicates of the time course experiments, all the 
samples derived from dexamethasone (Dex)-treated plants were labeled with one dye (i.e., 
Cy3), and all the samples derived from the corresponding Mock-treated plants were labeled 
with the alternative dye (i.e., Cy5). The dyes used for labeling RNA from a given treatment 
type (Dex and Mock) were switched for two of the replicate experiments, to reduce dye-
related artifacts. Dex- and Mock-derived samples for each timepoint and biological replicate 
were co-hybridized. This experimental setup resulted in a total of 5 hybridizations per set 
(0h, 2h, 4, 8h, and 12h; Dex vs. Mock at each timepoint), and two biological replicate sets 
labeled with each dye polarity (Mock-Cy3/Dex-Cy5, and vice versa). In the cycloheximide 
(Chx) experiments, samples from each biological replicate resulted in a set of four 
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hybridization pairs: Mock vs. Dex, Mock vs. Chx, Mock vs. Dex+Chx, and Chx vs. 
Dex+Chx.  Dye polarities were switched between biological replicates.  An additional 
microarray experiment, a comparison between ap1-1 mutant and wild-type inflorescences, 
was also carried out using Agilent version 1 microarrays.  The samples used in this 
experiment corresponded to the inflorescence meristem and floral buds, and have been 
described previously (S2). Three sets of biological replicates were used, and dye polarities 
were switched between them. 
Microarray data analysis. Raw data from the Operon microarrays, and feature extraction 
software pre-processed data from the Agilent Microarrays, were imported into the Resolver 
gene expression data analysis system version 7.1 (Rosetta Biosoftware, Seattle, WA) and 
processed as described (S1). Resolver uses a platform-specific error model-based approach 
to stabilize the variance estimation to improve the specificity and sensitivity in differential 
gene expression detection (S3). The data from the four biological replicates of each 
condition were combined, resulting in an error-model weighted average of the four. The P-
values for differential expression calculated by Resolver were adjusted for multi-hypothesis 
testing using the Benjamini & Hochberg procedure, as implemented in the Bioconductor 
multtest package in R 
(http://www.bioconductor.org/packages/bioc/stable/src/contrib/html/multtest.html). Genes 
for which the Benjamini & Hochberg-adjusted P-value was <0.05 in at least one of the 
comparisons (i.e., timepoints, for the time-course experiment) and microarray platforms 
used (Agilent and/or Operon) were initially considered differentially expressed in response 
to AP1 activation (Table S1). In the time course experiment, genes that were differentially 
expressed at timepoint 0h were excluded from the analysis. A further selection was 
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implemented by applying an absolute fold-change (FC) cutoff of 1.8, and resulted in the 
identification of a total of 1,370 genes that showed robust expression changes during the 
time-course experiment (Table S1).  Genes that were detected as differentially expressed in 
the Agilent time-course experiment (1017 genes) were subjected to cluster analysis using the 
k-means algorithm implemented in Resolver (Fig. 1B; Table S9).  Data from the 
cycloheximide experiment, in which Agilent version 2 microarrays were used, were 
processed in Resolver in the same manner, using a Benjamini & Hochberg-corrected P-
value<0.05 and an absolute FC>1.8 as cut-offs for differential gene expression.  The 
analysis of the data from the Mock vs. Dex, Mock vs. Chx, and Mock vs. Dex+Chx 
hybridizations revealed that the treatment with Chx caused considerable changes in gene 
expression (a total of 10,270 probes reported differential expression upon the Chx treatment, 
9,257 probes upon the Chx+Dex treatment, and 681 probes upon Dex treatment).  The data 
also indicated that the effects of Dex and Chx were largely additive rather than synergistic 
(data not shown).  As a result, additional Chx vs. Dex+Chx hybridizations were performed.  
With these datasets, genes that responded to AP1 activation in the presence of Chx (and are 
therefore potential direct AP1-targets), were identified using three different methods.  First, 
genes were selected if they were detected as differentially expressed upon both the Dex and 
Dex+Chx treatments but not upon the Chx treatment. Second, the Ratio-Split and Re-Ratio 
functions of Resolver 7.1 were used to computationally generate Chx vs. Dex+Chx 
comparisons, from which differentially expressed genes were selected with the same cutoffs 
indicated above.  Last, differentially expressed genes were also identified from the direct 
Chx vs. Dex+Chx hybridizations.  Combining these three strategies, a total of 1,578 genes 
were identified as potential AP1 targets (Table S5). Data from the comparison between ap1 
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mutant and wild-type inflorescences were also processed in Resolver. 
qRT-PCR experiments. cDNA synthesis was performed using DNase I-treated total RNA 
preparations (see above), oligo-dT primers and the RevertAid H Minus M-MuLV reverse 
transcriptase (Fermentas). Relative transcript abundance of selected genes (see Table S11 for 
a list of genes and the primers used) was determined using the Roche LightCycler 480 
system and the LC480 SYBR Green I Master kit (Roche Applied Sciences). Measurements 
were taken for three biologically independent sets of samples. In addition, all samples were 
analyzed twice. LightCycler melting curves were obtained for the reactions, revealing single 
peak melting curves for all amplification products. The amplification data were analyzed 
using the second derivative maximum method, and resulting Cp values were converted into 
relative expression values using the comparative Ct method (S4). Two reference genes 
(‘REF1’ and ‘REF2’; see Table S11) (S5) were used to normalize the data. Their Cp values 
were averaged for each sample.  
Antibodies. The coding region of AP1 was cloned as NdeI fragment into a pET-19b vector 
(Novagen, Madison, WI) and expressed in E. coli BL21 as a poly-histidine-tagged fusion 
protein. The recombinant proteins were purified under denaturing conditions using a 
guanidinium HCl-containing buffer for cell lysis on Ni-NTA agarose (Qiagen) according to 
the manufacturer’s instructions, and then resolved by preparative PAGE. A band 
corresponding to full-length AP1 was eluted and used to immunize rabbits. The resulting 
AP1 antiserum was affinity-purified using a C-terminal fragment of AP1 (which lacked the 
MADS domain) fused to glutathione S-transferase, which had been purified under native 
conditions. For ChIP-qPCR validation experiments, a commercial, affinity-purified peptide 
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antibody against GR (Affinity Bioreagents, PA1-516) was used for independent 
immunoprecipitations. 
Chromatin immunoprecipitation. For ChIP experiments, inflorescences of approximately 
4 week-old 35S:AP1-GR ap1-1 cal-1 plants were treated with a dexamethasone-containing 
solution (as described above). Inflorescence material from treated and untreated plants (0.8 
g) was collected 2 hours after the treatment and fixed for 30 min in 1% (v/v) formaldehyde 
and then quick-frozen in liquid nitrogen. The chromatin immunoprecipitation experiments 
and ChIP-Seq sample preparation were performed as described in (S6). One microgram of 
affinity-purified AP1 antibody (see above) was used for each ChIP experiment. Two 
independent sets of biological samples were used in two replicate experiments. 
Illumina ultra high-throughput sequencing and data analysis. ChIP-Seq libraries were 
sequenced using an Illumina Genome Analyzer II (Fasteris SA, Plan-les-Quates, 
Switzerland). Thirty-six cycles of sequencing were performed using the 36 Cycle 
Sequencing Kit v3. One or two flow-cell channels were run per sample, generating a total of 
more than 7 million sequence reads per sample. The raw sequence data were processed 
using the Illumina sequence data analysis pipeline GAPipeline1.3.2. Sequences in FASTQ 
format were mapped to the unmasked Arabidopsis genome (ATH1.1con.01222004; 
ftp://ftp.arabidopsis.org/) using the SOAP program (S7) (Table S10). A maximum of two 
mismatches and no gaps were allowed, and reads were iteratively trimmed from the 5’ end 
until mapped or their length fell below 31 nt. Only uniquely mapped reads were retained. 
Sequences mapping to the plastid and mitochondrial genomes were eliminated. Uniquely 
mapped reads were extended directionally to 300 bp, and enrichment of sample compared to 
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control was calculated using a score based on the Poisson distribution as described 
previously (S8) for each biological replicate independently. False discovery rate (FDR) 
thresholds were estimated by permutation of reads between sample and control. Afterwards, 
both biological replicates were combined conservatively by taking their minimum score at 
each nucleotide position. The most conservative threshold of both replicates was used to 
control the FDR. 
 To analyze the AP1 DNA binding regions for CArG box enrichment, perfect 
matches with CArG box (CC[W]6GG) and CArG box-like (C[W]7GG and CC[W]7G) 
consensus sequences were located in the 1,000-bp region around the maximum peak score 
position. The sequences of the regions were extracted from the Arabidopsis reference 
genome (ATH1.1con.01222004; ftp://ftp.arabidopsis.org/). In order to show the dependency 
of the enrichment on CArG boxes on the peak score value, only a region of 250-bp around 
the maximum peak score position was considered. For each score threshold considered, the 
proportion of significant peaks containing at least one CArG box was estimated. A control-
set of sequences was obtained by randomly permuting the nucleotide positions for each 
original 501-bp sequence, and CArG-box motif consensus sequences were located on the 
permuted sequences. This procedure was repeated 100 times to obtain the mean and the 
standard deviation of the proportion of significant peaks containing at least one CArG-box 
motif when the nucleotide sequences are permuted. 
All ChIP-Seq peaks were characterized by the relative position of the peak center 
(maximum score position) with respect to the 5' and 3' end of all annotated genes (as 
described in the TAIR8_GFF3_genes.gff file, ftp://ftp.arabidopsis.org/). Genes with at least 
one AP1 ChIP-Seq peak located within the region from 3 kb upstream of the 5'-end to 1kb 
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downstream of the 3'-end of the annotated transcript were considered as putative AP1 direct 
target genes (a total of 2,298 genes). In the majority of cases, the 5'-end of the annotated 
transcript marked the transcriptional start site (TSS). Out of 28,244 genes encoded in the 
Arabidopsis nuclear genome (TAIR8), 18,937 (67%) were annotated with a 5' UTR, 19,893 
(70%) with a 3' UTR, and 18,331 (65%) with both 5' and 3' UTRs. For the 2,298 genes 
identified as putative direct AP1 targets, the percentages were 79.7 % (5' UTR), 82.5 % (3' 
UTR), and 78.2 % (5' and 3' UTR). 
In order to estimate the level of enrichment of AP1 binding events in a region close 
to the start of genes, the method of Storey was applied (S9). In brief, given a set of values 
coming from two distributions, a uniform distribution representing the background level, 
and an unknown non-uniform distribution, representing the enriched positions, the 
proportion of values coming from each of these distribution is calculated separating the two 
densities. 
To determine the overlap between the AP1 binding sites identified in this study and 
those determined for SEP3 (S8), AP1 and SEP3 sites in each common putative direct target 
gene were paired as follows. For each gene, the relative peak position regarding the 5' end 
of the gene (if the peak is upstream of the gene), the 5’ end weighted by the length of the 
gene (if the peak is located inside the gene), or the 3’ end (if the peak is downstream) was 
used to unequivocally associate significant (FDR<0.001) AP1 peaks with their closest 
significant (FDR<0.001) SEP3 peaks. When two or more AP1 peaks had the same closest 
SEP3 peak, the SEP3 peak was assigned to the closest AP1 peak, and the other AP1 peaks 
were assigned to the next closest SEP3 peak (if any). In addition, the overlap between the 
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AP1 and SEP3 binding sites was also determined considering all possible AP1-SEP3 peak 
pairs per target gene, i.e., in a manner that was not peak-position directed (Fig. S10).  
ChIP-qPCR experiments. qPCR experiments were performed on immunoprecipitated 
DNA that was obtained using the GR antibody (see above) and tissue collected from 
untreated control plants, and from plants 2 and 12 hours after treatment with a 
dexamethasone-containing solution (as described above). qPCR experiments were done as 
two or more technical replicates using a Bio-Rad MyIQ Cycler and Bio-Rad iQ SYBR 
Supermix. Primers used for PCR amplification were designed surrounding the position of 
maximum height in the corresponding peak (i.e., the peak center) identified in the ChIP-Seq 
experiments, using the Primer3 program (http://frodo.wi.mit.edu/primer3/) (Table S12). The 
qPCR data were analyzed using the Biogazelle qBasePlus version 1.3 program. Two 
reference genes were used for normalization (see Table S12). 
Analysis of nuclear AP1-GR accumulation. Inflorescence tissue was collected from ap1-1 
cal-1 double mutants and from 35S:AP1-GR ap1-1 cal-1 plants at different time points after 
treatment with a dexamethasone-containing or a mock solution (as described above). The 
tissue was immediately frozen in liquid nitrogen. For each sample, nuclei were extracted by 
grinding 500 mL tissue in liquid nitrogen, followed by addition of 250 mL M1 buffer (10 
mM Na phosphate pH7.0, 100 mM NaCl, 1 M hexylene glycol (Sigma), 10 mM 2-
mercaptoethanol (Sigma), 1x Complete Protease Inhibitor Cocktail (CPIC; Roche)). The 
tissue was then ground again on ice and 650 mL M1 buffer were added. Subsequently, the 
cell suspension was filtered twice through Miracloth (Calbiochem) and the extract was 
centrifuged at 7,600xg, 5ºC for 1 min to pellet the nuclei. The supernatant was removed and 
the pellet washed in 900 mL M2 buffer (10 mM Na phosphate pH7.0, 100 mM NaCl, 10 
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mM MgCl2, 0.5% (v/v) Triton X-100 (Sigma), 1 M hexylene glycol, 10 mM 2-
mercaptoethanol, 1x CPIC), followed by centrifugation at 7,600xg, 5ºC for 1 min. Washes 
with M2 buffer were repeated twice. Subsequently, the pellet was resuspended in 900 mL 
M3 buffer (10 mM Na phosphate pH7.0, 100 mM NaCl, 10 mM 2-mercaptoethanol, 1x 
CPIC) and centrifuged at 2,000xg, 5ºC for 5 min. The pellet was then resuspended in 20 mL 
ChIP dilution buffer (16.7 mM Tris-HCl pH8.1, 167 mM NaCl, 1.2 mM EDTA, 1.1% (v/v) 
Triton X-100, 0.01% (w/v) SDS, 1x CPIC) and sonicated at high intensity for 5 cycles of 30 
sec using a Bioruptor (Diagenode). The resulting nuclear extract was centrifuged at 
20,000xg, 5ºC for 10 min to pellet membranes and insoluble proteins. After centrifugation, 
equal amounts of protein from the supernatants of the different samples were separated on 
12% SDS-PAGE gels, followed by transfer to a PVDF membrane and staining with Ponceau 
S. AP1-GR was detected using a polyclonal antiserum raised in rabbit against the rat 
glucocorticoid receptor (Affinity Bioreagents #PA1-516) at a final concentration of 2 
mg/mL in PBS-T (1xPBS with 0.05% (v/v) Tween 20) supplemented with 5% (w/v) milk 
powder. Histone 2A/B was detected using a polyclonal antiserum raised in rabbit (a gift 
from Dr. Thomas Kretsch, University of Freiburg), which was diluted 10,000-fold in 5% 
(w/v) milk PBS-T. The immunoblots were developed using horseradish peroxidase-coupled 
anti-rabbit IgG antibodies (Sigma; diluted 50,000-fold in PBS-T) and the ECL+ detection 
kit (GE) or the ECL kit (Pierce) for AP1-GR and histone 2A/B, respectively, according to 
the manufacturers’ instructions. 
Analysis of binding sites in TFL1. The lines SAIL351H08 and SAIL566G09 (accession: 
Columbia) were obtained from the European Arabidopsis Stock Centre 
(http://arabidopsis.info/) and contain T-DNA insertions 418 and 1615 bp, respectively, 
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downstream of the stop codon of TFL1 (in the intergenic region; the 3' untranslated region 
of TFL1 is 118 nucleotides long). The genotype of these lines was confirmed by PCR. The 
tfl1-1 mutant allele (accession: Columbia) has been previously described (S10). All plants 
were grown under standard long day conditions (16h light, 8h dark) at 22ºC. 
For complementation assays, we used different TFL1 constructs. pASM4 has been 
previously described (S11) and contains 1035 bp of TFL1 coding sequence, 2195 bp of 
genomic sequence upstream of the start codon and 4613 bp downstream of the stop codon 
of TFL1. It was made by ligating a 7843 bp XhoI/EcoRI fragment of Landsberg erecta 
genomic DNA into the SalI/EcoRI sites of the binary vector pBIN19. The pASM6 and 
pASAM8 constructs contained fragments including the TFL1 coding sequence and the 
genomic sequence upstream of the start codon, as in pASM4, but the sequences downstream 
of the stop codon were reduced to 432 bp in case of pASM6 and 1625 bp in case of pASM8. 
Both constructs were derived from pASM4, by replacing the 3’ sequence downstream of the 
stop codon with shorter 3’ fragments. These fragments were generated by PCR 
amplification and were subcloned using naturally occurring restriction sites in the TFL1 
genomic sequence. Full details of the cloning strategy are available upon request 
(madueno@ibmcp.upv.es). All constructs were transformed into homozygous tfl1-1 plants 
using the floral dip method (S12). For each genomic construct, several independent 
transgenic lines were obtained and analyzed (7 for pASM4, 31 for pASM6 and 65 for 
pASM8). 
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Figures and legends 
 
 
 
Figure S1:  Reproducibility of ChIP-Seq experiments. Average read-enrichment single-
nucleotide position scores for non-overlapping 1,000 bp regions across the Arabidopsis 
genome were plotted for the replicate ChIP-Seq experiments. The Pearson correlation 
coefficient for the data is 0.9 (and 0.84 for non-overlapping 100 bp regions), indicating high 
reproducibility of the experiments. 
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Figure S2: CArG box enrichment in AP1-binding genomic regions.  Left panels: 
location of perfect CArG boxes (CC[AT]6GG) (upper panel) and of CArG box-like 
sequences of type CC[AT]7G (lower panel) in genomic fragments identified by ChIP-Seq, 
using different FDR cut-offs (1942 regions were identified with FDR<0.001).  CArG box 
and CArG box-like sequences were predominantly found in the center of the genomic 
regions identified by ChIP-Seq (at the location of the peak maximum, or 0 position), and this 
positional enrichment increased with decreasing FDR cut-off values. Right panels: 
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distribution of CArG box-like sequences in the genomic regions bound by AP1. Black line: 
the proportion of genomic regions (defined as a 501 bp region centered around the location 
of the peak maximum) with CArG box (upper panel) and CArG box-like sequences (lower 
panel) at different peak score cut-off values (as determined in the ChIP-Seq analysis). Red 
solid line: permutation-derived background distribution of CArG box and CArG box-like 
sequences. Dashed red lines indicate one standard deviation from the mean.  
 
 
Figure S3: Relationship between AP1 binding events and target gene regulation.  (A) 
Approximately half of the genes identified through ChIP-Seq showed changes in gene 
expression after AP1 activation. The graph displays the proportion of differentially 
expressed genes among genes with a significant AP1 ChIP-Seq peak, at different threshold 
values (indicated on the x-axis). Genes identified through ChIP-Seq were those that showed 
at least one AP1 binding peak within 3 kb upstream of the 5' end and 1 kb downstream of 
the 3' end of the annotated gene.  With an FDR<0.001, used in this study to define the set of 
potential AP1 direct targets, a total of 2,298 genes were identified.  Of those, 2,183 genes 
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were represented in the arrays used in this study, and 46.3% of them (1011 genes) were 
detected as differentially expressed (Agilent and Operon datasets, Benjamini & Hochberg-
adjusted P-value <0.05; table S1).  (B) Approximately half of the AP1 binding sites 
identified through ChIP-Seq are near genes that showed changes in gene expression after 
AP1 activation. The graph displays the proportion of AP1 binding sites identified through 
ChIP-Seq, at different threshold values, that were near a gene that was detected as 
differentially expressed in the microarray experiments. With an FDR<0.001, used in this 
study, 1942 AP1 binding peaks were identified, and 1030 (53%) of them were located in the 
proximity of at least one differentially expressed gene (as defined in A).  If only ChIP-Seq 
peaks that are in the proximity of annotated genes are considered (1,678 of the 1,942), 
approximately 62% of them are nearby differentially expressed genes. 
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Figure S4: Validation of microarray results for selected genes by quantitative reverse 
transcriptase (qRT)-PCR. (A) Gene expression levels were determined in inflorescence 
tissue of 35S:AP1-GR ap1 cal plants treated for 12 hours with a dexamethasone-containing 
(red bars) or a mock solution (blue bars) and compared to those in untreated control plants. 
(B) Comparison of data from Agilent microarray experiments (12 h time point; orange bars) 
and qRT-PCR assays (brown bars). Log2 ratios are shown. Error bars indicate standard 
deviations of the experiments (qRT-PCR) and Resolver-calculated errors (microarrays). 
Gene aliases and corresponding gene identifiers are listed in Table S11. The putative 
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promoter regions of all genes tested are bound by AP1 according to the results of the ChIP-
Seq experiments, except in the case of TOE2, for which the closest AP1 ChIP-Seq peaks 
were located ~52 kb upstream and ~25 kb downstream from the start and end of the gene, 
respectively. With the exception of AP1, TOE2, SMZ, KAN, PHB, AFB2, ETT and PAP2, all 
genes were judged as differentially expressed in the microarray experiments upon AP1 
activation. For AP1, primers were used that are specific for the endogenous gene and thus, 
do not amplify transcripts stemming from the AP1-GR transgene. The agreement between 
the qRT-PCR results and those obtained in the microarray experiments indicates that the 
limited overlap between the ChIP-Seq and microarray-selected gene sets was not a result of 
low sensitivity and/or a reduced dynamic range of the microarrays used for our study. Five 
of the 7 genes (KAN, AFB2, ETT, PAP2, and PHB) that were not detected as differentially 
expressed by either method, had been identified by ChIP-Seq peak(s) specific to the gene 
(i.e., a peak that was not within 3 kb upstream or 1 kb downstream of any other gene); the 
SMZ peak had another associated gene, AT3G55000, which was not detected as 
differentially expressed in the microarray experiments; and the AP1 peaks were also 
associated to AT1G69130, which codes for a pre-tRNA (not represented in the microarrays 
used).  These observations suggest that the limited overlap between the ChIP-Seq and 
microarray-selected gene sets is not primarily a result of the intrinsic difficulties in assigning 
peaks to genes on the basis of distance.   
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Figure S5: Validation of ChIP-Seq results for selected AP1 binding sites. Quantitative 
PCR was done using genomic DNA as a template, which was obtained from inflorescence 
tissue of untreated 35S:AP1-GR ap1 cal plants, or from plants 2 or 12h after dexamethasone 
treatment (as indicated), and then subjected to ChIP with antibodies against the GR portion 
of the AP1-GR fusion protein. Normalized relative quantities of enrichment were calculated 
over the uninduced control ChIP sample and normalized using the two reference genomic 
regions (REF1 and REF2; see Table S12). Error bars indicate standard deviations. In most 
cases, the genomic regions that were amplified corresponded to the highest ChIP-Seq peaks 
within the 3 kb upstream to 1 kb downstream region of the respective genomic loci. In case 
of AP2 and TOE1, we selected peaks that were positioned approximately 4 kb (TOE1) or 3 
kb (AP2) upstream of the transcriptional start of the respective genes. Gene aliases and 
corresponding gene identifiers are listed in Table S12. 
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Figure S6: Relative AP1 ChIP-Seq peak position distribution with respect to the 5' end 
of genes. AP1 binding sites are enriched near the start site (5' end) of genes, and the level of 
enrichment varies when different groups of genes are considered. All significant AP1 peaks 
(FDR<0.001) within a distance of 30 kb upstream from the start of each gene in the 
respective group are included in the analysis. For each group of genes, the proportion of 
distances coming from the background level is calculated assuming that distances coming 
from it follow a uniform distribution, and that distances coming from a true enriched signal 
are non-uniform. To separate these two sets of distances, the method of Storey (S9) was 
used. Gene sets are as follows:  all TAIR8 annotated genes (black line; the proportion of 
distances stemming from the background level is 98.7%); high-confidence AP1 target genes 
(as defined in the article: adjusted P-value< 0.05 and fold change> 1.8 in Agilent and/or 
Operon microarray experiments, plus an AP1 ChIP-Seq peak in the -3kb to +1kb region with 
a FDR< 0.001) (green; 27%); genes that are differentially expressed (adjusted P-value< 
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0.05, no fold-change cut-off, Agilent dataset) (blue; 83.5%); genes that are differentially 
expressed minus the high-confidence AP1 target genes (grey; 92.9%); all TAIR8 annotated 
genes minus the high-confidence AP1 target genes (brown, 99.5%); and all TAIR8 
annotated genes minus genes that are detected as differentially expressed (i.e., genes that are 
not differentially expressed) (red; 100%).  When all high-confidence AP1 target genes are 
excluded from the group of differentially expressed genes, there is still enrichment of AP1 
binding sites with respect to the background level. 
 
 
Figure S7: Transcriptional responses of genes bound by AP1 during early flower 
development. (A) A subset of the genes that did not show a transcriptional response using 
our statistical selection criteria (adjusted P-value> 0.05), or (B) that responded only weakly 
(adjusted P-value< 0.05 and fold change< 1.8) to AP1 binding within the first 12h after AP1 
activation, showed significant changes in expression at more advanced stages of flower 
development. Both sets of genes were compared with a previously generated dataset 
stemming from the analysis of differential gene expression during early flower development 
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(days 1 to 5 after AP1 activation in AP1-GR ap1 cal inflorescences; data from (S1)). For 
each of the two sets of genes (A and B), blue bars indicate the number of AP1-bound genes 
that showed robust expression changes (adjusted P-value< 0.05 and fold change≥ 1.8) during 
early flower development, and black bars show the number of genes that responded only 
weakly (adjusted P-value< 0.05 and fold change< 1.8). The graphs display the number of 
genes first identified as differentially expressed in a given time point (i.e., genes are counted 
only once). All together (considering the two sets of genes in A and B), 136 genes (7% of the 
total) showed a robust transcriptional response, and an additional 497 genes (25%) a weak 
response. 
 
 
Figure S8: Nuclear accumulation of the AP1-GR fusion protein after dexamethasone 
treatment. Protein extracts were generated from nuclei isolated from inflorescence tissue of 
either ap1 cal double mutants (lane 1) or of 35S:AP1-GR ap1 cal plants (lanes 2-5). The 
latter plants were either treated with a mock solution (lane 2) or with a dexamethasone-
containing solution (lanes 3-5). From the plants treated with dexamethasone, tissue was 
collected after 1 d (lane 3), 3 d (lane 4) or 5 d (lane 5). The protein extracts were subjected to 
SDS-gel electrophoresis and then transferred onto a polyvinylidene fluoride (PVDF) 
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membrane for immunoblotting. Upper panel: results of an immunoblot using an α-GR 
antiserum. A band corresponding to the AP1-GR fusion protein (~63 kDa) is marked by an 
arrow. The approximate positions of protein size markers are indicated on the left. The 
results of the immunoblot show that AP1-GR strongly accumulated in nuclear extracts of 
dexamethasone-treated plants 1 and 3 d after the treatment. After 5 d, the amount of fusion 
protein detected in nuclear extracts was considerably lower than in the 1 and 3 d samples, 
suggesting that most of the AP1-GR protein that entered the nucleus in response to the 
dexamethasone treatment had been degraded or had undergone nuclear export. Center panel: 
the membrane shown in the upper panel was stripped and re-probed with an α-histone 2A/B 
antiserum. Bands corresponding to histone 2A and B are marked. Lower panel: Ponceau S 
staining of the PVDF membrane after protein transfer showing that approximately equal 
amounts of protein were present in each lane. The approximate positions of protein size 
markers are indicated on the left. 
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Figure S9: Network visualization of gene ontology (GO) categories enriched in the set of 
high-confidence AP1 target genes. GOslim categories with significant enrichment (adjusted 
P-values< 0.05) in the dataset are highlighted in color. Different colors represent different 
significance levels (as indicated). Diagram was generated using BiNGO version 2.3 (S13) 
and a GO Slim plant database. 
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Figure S10: ChIP-Seq and microarray results for selected AP1 target genes. (A) ChIP-
Seq results for selected target genes (as indicated). In each panel, the uppermost trace 
represents AP1 ChIP-Seq data followed by those for SEP3 (S8), which are shown for 
comparison. Genes found in the genomic regions analyzed, as well as their exon-intron 
structures, are indicated in the lower half of each panel. Scale bars indicate sequence lengths 
(in bp), and arrows gene orientations. The scale of the Y axis (peak height) is adjusted for 
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individual traces for visual clarity. (B) Transcriptional responses of the genes shown above 
after AP1 activation. The plot was generated using log2 ratios derived from (Agilent) 
microarray experiments. Timepoints are: 0h (white bar), 2h, 4h, 8h (grey scale), and 12h 
(black). 
 
 
Figure S11. Spatial distribution of AP1 and SEP3 binding sites. (A) All possible pair-wise 
position combinations of SEP3 and AP1 ChIP-Seq peaks in common target genes are depicted 
in the diagram. Binding data for SEP3 were taken from (S8). Transcribed regions are shaded 
in grey. Within transcribed regions, peak positions were calculated as a fraction of the gene 
length (see Fig. 1F). The density of peak pairs in the graph is represented with a color scale 
(Counts; number of peak pairs per area unit). Because for the AP1 and SEP3 peaks associated 
with a target gene, no positional information (with respect to the gene and to each other) is 
considered for pairing the peaks, but rather, all possible combinations are calculated, the 
results exclude the possibility of positive biases caused by position-directed peak pairing.  (B) 
Distance distribution of SEP3 and AP1 binding sites in common target genes. Each bar 
represents a 100-bp window. 
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Tables and legends 
Table S1: Genes identified as differentially expressed after AP1 activation.  Genes for 
which the Benjamini & Hochberg-adjusted P-value was <0.05 in at least one of the 
timepoints and microarray platforms used (Agilent and/or Operon) were initially considered 
as differentially expressed in response to AP1 activation ("Agilent and_or Operon_BH-0h" 
worksheet). Genes that were differentially expressed at timepoint 0h were excluded from the 
analysis of the corresponding platform data. Results are summarized per time point (0h, 2h, 
4h, 8h, 12h), platform (Agilent or Operon) and, in the case of the Operon oligo microarrays, 
per scanner used (GenePix 4200A or 4000B), and arranged accordingly in columns (0h 
Agilent, 0h Operon 4200 SCAN, 0h Operon 4000 SCAN, 2h Agilent, etc.) using values of 
"0" (no differential expression) and "1" (differential expression).  Fold change, P-value, and 
Benjamini & Hochberg-adjusted P-value (BH) are also shown. A gene may be listed more 
than once if probes assigned to different gene models or variants were present, either within 
or across platforms. A total of 6600 different genes (using probes for 6731 different 
gene/gene variants) were identified as differentially expressed.  A further selection for robust 
differential expression was implemented by applying an absolute fold-change (FC) cutoff of 
1.8 ("Agilent and_or Operon BH&FC-0h" worksheet), which led to the identification of 1366 
different genes (using probes for 1392 gene/gene variants). 
Supplementary file: Table S1.xls 
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Table S2: Genomic regions identified as enriched in AP1 ChIP-Seq experiments. A total 
of 14,174 genomic regions were identified in the AP1 ChIP-Seq experiments ("ChIP-Seq 
peaks" worksheet), 1,942 of which were classified as statistically significant (FDR<0.001, 
which corresponded to a peak score >79.6). Of those 1,942 enriched regions, 1,678 were 
within 3 kb upstream from the start to 1 kb downstream from the end of TAIR8 annotated 
genes: a total of 2298 different genes were identified, which resulted in 2,653 different peak-
gene combination ("ChIP-Seq peak - Gene pairs" worksheet; one peak can be associated with 
more than one gene, and vice versa). These 2,298 genes are classified as "Putative direct 
targets".  The position of the peak with a score higher than 79.6 (or peaks, if more than one 
peak above that threshold is associated with a gene) with respect to the corresponding gene is 
indicated by dividing the gene region into different segments: from 3000 bp to 2001 bp 
upstream of the start, from 2000 to 1001 bp upstream, from 1000 bp upstream to the 5' end, 
from 250 bp upstream to the 5' end, within the annotated gene region (5' - 3' end), and from 
the end of the annotated gene to 1000 bp downstream. The maximum peak score within the 
indicated regions is shown in the columns.  A value of 0 indicates that no peak in that region 
was above the score threshold of 79.6. Gene symbols and sequence annotation (Sequence 
Description) are provided for the identified genes. Columns in the "ChIP-Seq peaks" 
worksheet show: a unique identifier for each peak, which consists of the chromosome 
number and the coordinate position for the peak maximum (ChIP-Seq peak ID column); the 
start and end coordinates of the peak region (Start coordinates, End coordinates); the 
position, in chromosome coordinates, of the nucleotide within the peak with the highest score 
(ChIP-Seq peak score position); the peak score, which is the maximum score of any of the 
nucleotides encompassed by the peak (ChIP-Seq peak score); and the distance between the 
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start and the end of the peak (Peak length). Additional columns in the ChIP-Seq peak - Gene 
pairs worksheet show: the position of the peak with respect to the gene (Relative position to 
the start of the gene, and Relative position to the end of the gene), a unique identifier for the 
gene associated with the peak (Gene ID (At#)), and the distance from the start to the end of 
the gene according to TAIR8 annotation (Gene length). 
Supplementary file: Table S2.xls 
 
Table S3: High-confidence AP1 targets.  High-confidence target genes were those 
identified as differentially expressed (BH< 0.05 and FC> 1.8) and for which a ChIP-Seq AP1 
binding site was detected (FDR< 0.001, peak score> 79.6) within the region from 3 kb 
upstream from the start to 1 kb downstream from the end of the annotated gene (see Fig. 1D).  
For each gene, both the ChIP-Seq results and the microarray data are presented in the table. 
The position of the peak with a score higher than 79.6 (or peaks, if more than one peak above 
that threshold is associated with a gene) with respect to the corresponding gene is indicated 
by dividing the gene region into different segments: from 3000 bp to 2001 bp upstream of the 
start, from 2000 to 1001 bp upstream, from 1000 bp upstream to the 5' end, from 250 bp 
upstream to the 5' end, within the annotated gene region (5' - 3' end), and from the end of the 
annotated gene to 1000 bp downstream. The maximum peak score within the indicated 
regions is shown in the columns.  A value of 0 indicates that no peak in that region was 
above the score threshold of 79.6. Gene symbols and sequence annotation (Sequence 
Description) are provided for the identified genes. Microarray results are summarized per 
time point (0h, 2h, 4h, 8h, 12h), platform (Agilent or Operon) and, in the case of the Operon 
oligo microarrays, per scanner used (GenePix 4200A or 4000B), and arranged accordingly in 
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columns (0h Agilent, 0h Operon 4200 SCAN, 0h Operon 4000 SCAN, 2h Agilent, etc.) using 
values of "0" (no differential expression) and "1" (differential expression).  Fold change, P-
value, and Benjamini & Hochberg-adjusted P-value (BH) are also shown.  The table is non-
redundant, and genes are listed only once. 
Supplementary file: Table S3.xls 
 
Table S4: Classification of all genes represented on the Agilent or Operon microarrays 
with respect to their differential expression and their identification as AP1 target. The 
proportion of differentially expressed genes showing a strong transcriptional response (BH< 
0.05 and FC> 1.8) was significantly larger among AP1 targets (11.41%; 249 out of 2183) 
(targets selected at FDR< 0.001) than among non-targets (4.31%; 1117 out of 25942) as 
revealed by a chi-square test for equality of proportions (with 1 degree of freedom, P-value< 
0.001). 
 
Was AP1 target? Gene No Yes Margin 
No 24825 1934 26759 Was differentially 
expressed? Yes 1117 249 1366 
Margin 25942 2183 28125 
 
 
 
Table S5: Microarray results of the cycloheximide experiment. Three different strategies 
were used to identify genes that respond transcriptionally to AP1 activation in the presence of 
the translational inhibitor cycloheximide (see Materials and Methods): direct Dex vs. 
Dex+Chx microarray hybridizations ("Direct comparison" worksheet); Dex vs. Dex+Chx 
comparisons created via a re-ratio analysis ("Re-ratio comparison" worksheet); and 
comparison of the Mock vs. treatment hybridizations, where genes were selected if they were 
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detected as differentially expressed upon both the Dex and Dex+Chx treatments but not upon 
the Chx treatment ("Indirect comparison" worksheet).  In all cases, genes were deemed as 
differentially expressed if Fold change>1.8 and Benjamini & Hochberg-adjusted P-value 
(BH) <0.05.  Fold change, P-value, and adjusted P-value (BH) are shown.  The table is 
redundant, and genes may be listed more than once, because for some genes more than one 
probe was present on the microarrays used.  Agilent version 2 microarrays were used in the 
cycloheximide experiments, and a total of 87 out of the 197 high-confidence targets (44%) 
that were detected as such with Agilent version 1 arrays in the time course experiment, 
responded transcriptionally in the absence of protein biosynthesis. The proportion of 
differentially expressed genes in the presence of CHX was significantly larger among 
Agilent-identified high-confidence AP1 targets (87 out of 197, 44.16%) than among non-
targets (1491 out of 28130, 5.30%) as revealed by a chi-square test for equality of 
proportions (with 1 degree of freedom, P-value < 0.001) (worksheet "chi-square"). 
Supplementary file: Table S5.xls 
 
Table S6: Necessity and sufficiency of AP1 for affecting the expression of high-
confidence target genes. To obtain evidence for the necessity of AP1 as an inductive (or 
repressing) factor of the high-confidence target genes, we performed a gene expression 
profiling experiment comparing ap1-1 mutant and wild-type inflorescences using Agilent 
version 1 microarrays (worksheet "AP1 necessity (ap1 vs wt)"). If AP1 activity were 
necessary, AP1 target genes that were found to be induced upon AP1-GR activation would 
be expected to be down-regulated when comparing gene expression in ap1 versus wild-type 
inflorescences and, conversely, AP1 target genes that were repressed after AP1-GR 
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activation would be expected to be up-regulated in the ap1 versus wild type comparison, as 
ap1-1 is a loss-of-function mutant. Sixteen genes (out of the 197 high-confidence targets that 
were identified through the Agilent microarrays; Table S3) showed expression changes in the 
ap1 vs wild type comparison that followed the above logic.  That this percentage is low 
(8.1%) is expected, given that the plant materials and the developmental stages that were 
assayed in the AP1-GR ap1 cal time course and in the ap1 versus wild type comparison were 
necessarily different, and because in ap1 mutant plants the (partially) functionally redundant 
homolog CAL is present (and therefore masks part of the effects of the loss of AP1 function).  
For the sixteen genes, the table shows: Fold change and P-value for the ap1 vs. wild type 
experiment; and Fold Change, P-value, and adjusted P-value (BH) for the timepoint 
(indicated) at which strong differential expression (FC>1.8, BH<0.05) was first detected in 
the time course experiment. The complete ap1 versus wild type microarray dataset is 
available in the Gene Expression Omnibus under accession number GSE20138. To obtain 
evidence for the sufficiency of AP1 as an inductive (or repressing) factor of the high-
confidence target genes, we compared the list of such genes with the results of the 
cycloheximide experiment (worksheet "AP1 sufficiency (CHX)").  Targets that are induced 
(or repressed) after AP1-GR activation, and that show a similar change in expression when 
AP1-GR is activated in the presence of cycloheximide (i.e., in the absence of protein 
synthesis) represent genes for which AP1 is, in a floral context, sufficient to exert the 
expression change. A total of 81 targets (41%) were identified. For the 81 genes, the table 
shows Fold Change, P-value, and adjusted P-value (BH) for the timepoint (indicated) at 
which strong differential expression (FC>1.8, BH<0.05) was first detected in the time course 
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experiment, and for the three different analysis methods used in the cycloheximide 
experiment (the cycloheximide results are described in full in table S5). 
Supplementary file: Table S6.xls 
 
Table S7. Classification of transcription factor-coding genes represented on Agilent or 
Operon microarrays with respect to their differential expression and their identification 
as AP1 target. The fraction of transcription factor-coding genes showing a strong 
transcriptional response (BH< 0.05 and FC> 1.8) is significantly larger among AP1 targets 
(18.51%; 62 out of 335) (targets selected at FDR < 0.001) than among non-targets (7.43%; 
102 out of 1373) as revealed by a chi-square test for equality of proportions (with 1 degree of 
freedom, P-value < 0.001). 
 
Was AP1 target? Gene No Yes Margin 
No 1271 273 1544 Was differentially 
expressed? Yes 102 62 164 
Margin 1373 335 1708 
 
 
Table S8: Phenotypes observed for the main inflorescences of tfl1 T-DNA insertion 
mutants and of transgenic lines derived from the transformation of tfl1-1 plants with 
fragments of the TFL1 genomic region. 
 
Genotype nc Cauline 
leavesd 
Axillary 
flowersd,e 
Determinate 
coflorescencesd, 
f 
Indeterminate 
coflorescencesd,g 
No. of 
flowersd,h 
Terminal 
flower 
(%)i 
Wild type 
Columbia 
20 3±0.9 0 0 3±0.9 36.3±4.8 0 
tfl1-1 47 1.5±0.7 1.4±0.7 0 0 2.2±1.2 100 
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tfl1-1 
pASM4a 
7 4.4±1.3 0 0 4.4±1.3 43.7±0.5 0 
tfl1-1 
pASM8a 
65 2.4±0.9 0.03±0.2 2.3±0.9 0 5.3±2.9 100 
tfl1-1 
pASM6a 
31 1.5±08 1.4±08 0.±0.2 0 2.7±1.2 100 
∇ 1615b 8 1.4±0.5 0.1±0.4 1.3±0.7 0 6.4±1.2 100 
∇  418b 11 1.2±0.6 1±0.5 0.2±0.4 0 3.8±1.2 100 
 
a Transgenic lines derived from the transformation of tfl1-1 with fragments of the TFL1 gene 
containing the intergenic region upstream the start codon, the TFL1 coding sequence and 
4613 bp (pASM4), 1625 bp (pASM8) or 432 bp (pASM6) of the sequence downstream the 
TFL1 stop codon. 
b Lines with T-DNA insertions at 1615 bp or 418 bp downstream of the stop codon of TFL1. 
c Number of plants analyzed. For tfl1-1, ∇1615 and ∇418, homozygous mutant plants were 
analyzed. For tfl1-1 plants transformed with genomic constructs, the data correspond to the 
average of the indicated number of independent T1 plants. 
d Values are expressed as mean±SD. 
e Number of solitary flowers formed in the axil of a cauline leave. 
f Number of coflorescences that formed a terminal flower. 
g Number of coflorescences that did not form a terminal flower 
h Number of flowers produced by the main inflorescence stem before cessation of growth. 
i  Percentage of plants whose main inflorescence formed a terminal flower. 
 
 
Table S9: Clustering analysis of differentially expressed genes. Genes identified as 
differentially expressed (Benjamini & Hochberg-adjusted P-value <0.05 and FC>1.8) in the 
Agilent time course microarray experiments and that were subjected to cluster analysis are 
shown in the table.  The cluster in which each gene was grouped (Cluster Number; 1 through 
6, as in Fig. 1B) is indicated. 
Supplementary file: Table S9.xls 
 
Table S10: Mapping results for the Illumina sequencing runs. Results are shown per flow 
cell lane. The number of reads (sequences) that were mapped in the Arabidopsis 
chromosomes (chr1-5), and in the chloroplast and mitochondrial genomes, is indicated, as 
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well as the total number of mapped reads. Column "% chr1-5" shows the percent of the total 
number of reads that was mapped to chromosomes 1 through 5 (i.e., excluding chloroplast- 
and mitochondria-mapped reads). 
Mapping results Illumina 
Sequencing 
run (lanes) chrC chrM chr1-5 
Total number of 
mapped reads % chr1-5* 
Total 
number 
of reads 
Replicate 1 
uninduced 1 108263 50471 1715147 1873881 49.3 3479131 
Replicate 1 
uninduced 2 166430 149641 3234895 3550966 43.7 7405077 
Replicate 1 
induced 99155 42967 3355117 3497239 46.9 7154722 
Replicate 2 
uninduced 1 92817 14725 2221675 2329217 48.0 4627140 
Replicate 2 
uninduced 2 183799 39433 3725948 3949180 38.7 9636656 
Replicate 2 
induced 1 85198 16261 3151437 3252896 64.9 4854426 
Replicate 2 
induced 2 179239 43248 6321287 6543774 60.9 10371555 
  * Regarding the total number of reads 
 
Table S11: Primers used for qRT-PCR assays. Gene identifiers, gene aliases and primer 
sequences are shown.  
Gene ID Alias 5’ Primer 3’ Primer 
AT3G26810 AFB2 5’-ACTTCAGCGGTTAT
GGATTTTGG-3’ 
5’-AGATTTCCACACCTCTTT
GCTTG-3’ 
AT1G69120 AP1 5’-ATTAGCAGGCTCCT
TTCTTCTTTTG-3’ 
5’-CCCTGATACCCGATCTG
AAGAATG-3’ 
AT3G54340 AP3 5’-TCCGGACTCAGATC
AAGCA-3’ 
5’-CATTGCTAGCGATAGAT
CGCTC-3’ 
AT2G33860 ETT 5’-AACAACTGGTCCCA
AGAGAAGC-3’ 
5’-ACATCTGGGTCTATCAT
CACCA-3’ 
AT4G35900 FD 5’-TCTCTCTACTCCCTC
TCTGCG-3’ 
5’-CCGAGGCTAGATGTGTT
GTAGAG-3’ 
AT2G17770 FDP 5’-CAGGCATATACAAA
CGAACTTGAGC-3’ 
5’-TGAGAGTCTGGTTCTTG
TTTGTAGC-3’ 
AT5G16560 KAN 5’-GTAACTCTTCAGGA 5’-GCAAGACCCTCTGGAAT
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GAGACATGGC-3’ CTCAATG-3’ 
AT5G61850 LFY 5’-CGTTTATCGTAACG
GAGCCTGG-3’ 
5’-TTGAGTTGCTTCGGCTA
TTTTCAG-3’ 
AT4G29080 PAP2 5’-CAGTGACTGGATGC
TGGTCG-3’ 
5’-CTAGACCTTCTTCGGTC
ACAGC-3’ 
AT2G34710 PHB 5’-CGAACCTGGTCGTA
AAGCTCTTTG-3’ 
5’-CTTACCGTATAAACCCA
TCGTGGAC-3’ 
AT1G13320 REF1 5’-AAGCGGTTGTGGAG
AACATGATACG-3’ 
5’-AGTTCACGTTCATTCTCT
CTGACC-3’ 
AT4G34270 REF2 5’-ATCTGCGAAAGGGT
ATCCAGTTGAC-3’ 
5’-TGGAGAGCTTGATTTGC
GAAATACCG-3’ 
AT1G24260 SEP3 5’-CTCTAAGACTAAGG
TTAGCTGATGGG-3’ 
5’-CTGAATACTTGGTTCGT
CACCTTGG-3’ 
AT3G54990 SMZ 5’-CAATGAGTTGGGAA
AGGGAGAAGG-3’ 
5’-CTTACCGTATAAACCCA
TCGTGGAC-3’ 
AT2G39250 SNZ 5’-AGTTGGGTGCCCAT
AGTAAAGG-3’ 
5’-CCATGCTTGACGCACAT
ACTCC-3’ 
AT5G03840 TFL1 5’-TCCTTCTTCTGTTTC
CTCCAAG-3’ 
5’-TTCCATTTCATCCTCAAG
ACG-3’ 
AT2G28550 TOE1 5’-CAGCGTGGAGTTAG
CTTGAGG-3’ 
5’-CTTCCCATGCAAACTCG
TCAC-3’ 
AT5G60120 TOE2 5’-GGTCTCTATGTTATC
CACCCATCTG-3’ 
5’-CGTTCCAGTAAAGGCGA
TGATCC-3’ 
AT5G67180 TOE3 5’-GATCTTAGCTCAGA
GACGACGAG-3’ 
5’-GCTGTGTAGAACCTTGA
GTTATGCG-3’ 
 
Table S12: Primers used for ChIP-qPCR assays. Gene identifiers, gene aliases and primer 
sequences are shown. 
Gene ID Alias 5’ Primer 3’ Primer 
AT4G35900 FD 5’-TATCTTCTTTTGGCC
CAATTTCATTT-3’ 
5’-TTGGTTGCTTAAAAGA
ATACACAGCA-3’ 
AT1G69120 AP1 5’-GGAGATCATGAGCA
AAAGTAGTAAGCA-3’ 
5’-TGGAGATGTAACAAA
GGCGAAGATAA-3’ 
AT2G39250 SNZ 5’-CAATAATGGAGTGA
AATGGAACGTGT-3’ 
5’-TCTACCTCTCTCTCCC
CTCCACATAC-3’ 
AT2G28550 TOE1 5’-CCATCATGGTAAGTG
GTAACCAAGTC-3’ 
5’-GAGACCCATTATTGGG
AGTAACCAAA-3’ 
AT4G36920 AP2 5’-TCATATATGTCGCAT
AACGAGGGAGT-3’ 
5’-TGCTCATATAAAACAA
AACCAAAGAAACA-3’ 
AT5G61850 LFY 5’-TGCATGCATTCACAC
ATAGTACACAT-3’ 
5’-TATTATCCGCCGAGCA
ATAGACTGTA-3’ 
AT4G18960 AG 5’-GAACGTTGTGATGTT 5’-TCAACAACCCATTAAC
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ACTCGGACAAG-3’ ACATTGGGTA-3’ 
AT1G24260 SEP3 5’-AAACCCAGACGTGA
CTTGTTTGACG-3’ 
5’-TGAGAATCGGACGGC
TTTGAGG-3’ 
AT3G54340 AP3 5’-CAATTGATTTAAGCA
GTGTC-3’ 
5’-GGAAAGTATTGCCTA
ATCCATGAAAG-3’ 
AT4G26930 REF1 5’-TCTCCGACCTTTCTT
CACACCCATTCC-3’ 
5’-GTCTCCGCTTAGGAGC
ACGAAAGCTATC-3’ 
AT4G17740 REF2 5’-GCTATCCACAGGTTA
GATAAAGGAG-3’ 
5’-GAGAAAGATTGTGTG
AGAATGAAA-3’ 
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